
-
Agenus Inc. NasdaqCM:AGEN Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Location: 3 Forbes Road, Lexington, MA, 02421-7305, United States | Website: https://www.agenusbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
187M
Cash
18.49M
Avg Qtr Burn
-36.44M
Short % of Float
15.10%
Insider Ownership
1.42%
Institutional Own.
34.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Metastatic colorectal cancer (mCRC) | Phase 2 Data readout | |
Botensilimab (AGEN1181) (anti-CLTA-4) Details Pancreatic cancer, Melanoma Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout | |
AGEN1777 (BMS-986442) (TIGIT)+ nivolumab and/or chemotherapies Details Cancer, Non-small cell lung carcinoma, Solid tumor/s, Lung cancer | Phase 2 Update | |
Botensilimab (AGEN1181) Details Cancer, Non-small cell lung carcinoma | Phase 1b Data readout | |
AGEN2373 w/ Botensilimab (AGEN1181) Details Solid tumor/s, Cancer, Melanoma | Phase 1b Update | |
Botensilimab (AGEN1181) w/ Balstilimab (AGEN2034) Details Cancer, Ovarian cancer | Phase 1b Update | |
Botensilimab (AGEN1181) + balstilimab Details Cancer, Sarcoma | Phase 1b Update | |
AGEN1571 w/ Botensilimab (AGEN1181) & Balstilimab (AGEN2034) Details Hepatocellular Carcinoma | Phase 1 Update | |
AGEN1423 (anti-CD73-TGFβ-trap bifunctional antibody) + balstilimab (anti-PD-1) Details Pancreatic cancer, Cancer | Failed Discontinued | |
Balstilimab (AGEN2034) Details Cancer, Cervical cancer | Failed Discontinued | |
Balstilimab (anti- PD-1) + Zalifrelimab (anti-CTLA-4) Details Cancer, Cervical cancer | Failed Discontinued |